Biofrontera Inc
$ 0.72
0.17%
26 Dec - close price
- Market Cap 8,400,800 USD
- Current Price $ 0.72
- High / Low $ 0.75 / 0.72
- Stock P/E N/A
- Book Value -0.22
- EPS -1.50
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.65 %
- ROE -11.92 %
- 52 Week High 1.24
- 52 Week Low 0.54
About
Biofrontera Inc. is a biopharmaceutical company headquartered in Woburn, Massachusetts, specializing in the development and commercialization of innovative dermatological therapies for various skin conditions. The company focuses on leveraging its proprietary technologies to enhance treatment efficacy and improve patient outcomes, positioning itself as a significant player in the U.S. dermatology market. With a commitment to advancing dermatological care, Biofrontera is strategically expanding its product portfolio to solidify its leadership in the industry and address the evolving needs of patients and healthcare providers.
Analyst Target Price
$6.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-13 | 2025-05-13 | 2025-03-13 | 2024-11-13 | 2024-08-14 | 2024-05-15 | 2024-03-15 | 2023-11-09 | 2023-08-11 | 2023-05-12 | 2023-03-08 |
| Reported EPS | -0.62 | -0.57 | -0.5084 | -0.232 | -0.8138 | -0.05 | -2.88 | 1.65 | -4.64 | -7.23 | -0.28 | -0.14 |
| Estimated EPS | -0.57 | -0.57 | -0.29 | -0.07 | -0.83 | -0.77 | -1.17 | -1.19 | -3.78 | -4.61 | -0.19 | -0.11 |
| Surprise | -0.05 | 0 | -0.2184 | -0.162 | 0.0162 | 0.72 | -1.71 | 2.84 | -0.86 | -2.62 | -0.09 | -0.03 |
| Surprise Percentage | -8.7719% | 0% | -75.3103% | -231.4286% | 1.9518% | 93.5065% | -146.1538% | 238.6555% | -22.7513% | -56.833% | -47.3684% | -27.2727% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BFRI
2025-12-18 18:09:12
Biofrontera Inc. has finalized the transfer of FDA approvals for its Ameluz and RhodoLED Lamp Series, including the NDA and IND, gaining full control over development, manufacturing, and marketing in the U.S. The company has also initiated the transfer of associated intellectual property and trademarks. This move is a significant step in Biofrontera's strategic transformation, following an $11.0 million investment, as it continues clinical trials to expand the use of its PDT products for non-melanoma skin cancers and acne.
2025-12-18 18:08:55
Biofrontera Inc. has finalized the transfer of FDA approvals for its Ameluz and RhodoLED Lamp Series products, gaining full control over clinical development, manufacturing, and marketing in the U.S. This includes intellectual property assets and was partially secured by an $11.0 million investment. The company specializes in photodynamic therapy for dermatological conditions and is expanding its product use through clinical trials, despite recent financial losses.
2025-12-18 14:08:44
Biofrontera Inc. has completed the transfer of FDA approvals and associated intellectual property for Ameluz and the RhodoLED lamp series, effective December 17, 2025. This move gives Biofrontera full US regulatory control over these assets, including 11 granted US patents, 10 US patent applications, and 19 international filings. The asset transfers were supported by an $11.0 million investment, positioning the company to independently manage clinical development, manufacturing, and marketing in the US.
2025-12-18 08:45:00
Biofrontera Inc. has announced the completion of the transfer of FDA approvals for Ameluz® and the RhodoLED® Lamp Series, including the NDA and IND, to Biofrontera as of December 17, 2025. This action gives Biofrontera full control over ongoing clinical development, manufacturing, and marketing in the US. The company also completed filings to transfer associated US and international intellectual property, strengthening its market position.
2025-12-18 08:45:00
Biofrontera Inc. has announced the completion of the transfer of FDA approvals for Ameluz® and the RhodoLED® Lamp Series, including the NDA and IND, to Biofrontera. The company also completed filings to transfer US and international intellectual property associated with these products. This strategic move aims to consolidate control, drive operational efficiencies, and accelerate the pursuit of new indications for their photodynamic therapy products.
2025-12-06 05:09:16
Biofrontera Inc. has completed a Phase 1 pharmacokinetic study for its Ameluz gel, aiming to expand its approved treatment areas for actinic keratoses to include the neck, trunk, and extremities. The company plans to submit a supplemental New Drug Application to the FDA in summer 2026, leveraging data from this study and a recently completed Phase 3 clinical trial. This move addresses the significant public health issue of actinic keratoses, which affected approximately 58 million Americans in 2020.
